Precision Medicine in Oncology: In Vitro Drug Sensitivity and Resistance Test (DSRT) for Selection of Personalized Anticancer Therapy

Anna A. Popova,Pavel A. Levkin

DOI: https://doi.org/10.1002/adtp.201900100

IF: 5.003

2020-01-16

Advanced Therapeutics

Abstract:Precision or personalized medicine aims to determine an optimal therapy for each individual patient. In oncology techniques such as next generation sequencing, mRNA‐sequencing, ChIP‐sequencing, and mass spectrometry are used to perform a full molecular profiling for each patient. However, it is not always possible to determine a suitable treatment for an individual cancer based on molecular profiling, mostly due to the high level of tumor heterogeneity. In vitro drug sensitivity and resistance test (DSRT) can be performed on cancer cells or tissues obtained from a patient with a panel of anticancer compounds in order to experimentally define sensitivity and resistance of each individual cancer. In combination with molecular profiling, DSRT can provide a fuller picture about the nature of disease, allowing for finding more appropriate therapy for each individual patient. In this progress report, studies describing in vitro DSRTs on 2D and 3D cell models based on patient‐derived cells are reviewed and challenges and future steps needed for the adaptation of these systems in clinics are discussed. Precision medicine aims to determine an optimal therapy for each patient. In vitro drug sensitivity and resistance tests (DSRTs) are performed on patient cancer cells with anticancer drugs in order to define sensitivity and resistance of individual cancer. In this progress report, studies describing DSRT are reviewed and challenges and future steps needed for its adaptation in clinics are discussed.